Eli Lilly Stock Soars on FDA Approval

LLY is up 30% in the last 12 months

Digital Content Manager
May 29, 2020 at 10:45 AM
facebook X logo linkedin


The shares of Eli Lilly (NYSE: LLY) are up 0.3% to trade at $150.22 this morning, after the Food and Drug Administration (FDA) approved the use of TAUVID, the first radioactive agent to detect an abnormal protein that is characteristic of Alzheimer's disease. Before this approval the only diagnosis method available for Alzheimer's disease was autopsy. 

Prior to today's breakthrough, analysts had been optimistic about the drugmaker, with six of the nine in coverage sporting a "strong buy", compared to three calling it a "hold" and not a single "sell" in sight. Meanwhile, Eli Lily's 12-month consensus target price sits at $156 -- a 3.5% premium to its current perch -- implying the equity is ripe for price-target hikes in the future.

Digging deeper, LLY shares have been on a steady climb since late 2019, now sitting at a 30% year-over-year surplus. In late April, the shares hit at an all-time-high of $164.90, cooling off slightly in recent weeks but finding support at their 80-day moving average.

It is no wonder then that calls have been so popular in the options pits. In the last 50 days, 2.33 calls were bought for every put at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). This ratio sits higher than 98% of readings from the past year, meaning calls are being picked up at a faster-than-usual clip.  

Those options traders are in luck, because LLY premium is affordably priced at the moment. The security's Schaeffer's Volatility Index (SVI) of 28% sits in the 18th percentiles of all other readings from the past year. This means options players have been pricing in relatively low volatility expectations at the moment.  

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI